All patients treated with SPINRAZA who were alive at the time of
the interim efficacy analysis either maintained or improved their HINE Section 2 scores.1
A planned
interim efficacy analysis was conducted based on 82 patients who completed at least 183 days of treatment, withdrew from the study, or died.